|
Feb 14
|
Controlling risk is still the biggest concern for insurers with cyber insurance
|
|
Feb 14
|
AI-driven virtual care revolutionises patient safety and hospital efficiency
|
|
Feb 14
|
Heating up: heatwaves associated with increased ischaemic stroke risk
|
|
Feb 14
|
Pfizer’s Talzenna gains 14-months OS lead over mCRPC SoC
|
|
Feb 14
|
The future of renewable fuels in the energy mix
|
|
Feb 14
|
DMD market expected to grow to $5.2bn in the 7MM by 2033
|
|
Feb 14
|
AI ethics: what are the limits in healthcare?
|
|
Feb 14
|
BMJ’s Phase III Opdualag study fails to meet endpoints
|
|
Feb 14
|
Moderate to intense exercise in childhood reduces smoking in adulthood
|
|
Feb 13
|
Assessing the biggest refinery technology changes by 2030
|
|
Feb 13
|
‘No trade-off between AI regulation and innovation’ – GlobalData
|
|
Feb 13
|
Trump presidency signals potential downturn in NIH SBIR/STTR grant funding for biopharma drugs
|
|
Feb 13
|
Semaglutide cuts alcohol cravings but not daily drinks in Phase II trial
|
|
Feb 13
|
Royalty Pharma pays $250m for rights to Biogen’s lupus drug
|
|
Feb 13
|
Repeated corporate governance failures damaging consumer trust – report
|
|
Feb 12
|
AnaptysBio achieves ‘highest ever’ results in Phase II rheumatoid arthritis trial
|
|
Feb 12
|
OCT West Coast 2025: China surpasses US for annual number of clinical trials
|
|
Feb 12
|
Lack of expertise is biggest challenge for insurers in implementing AI
|
|
Feb 12
|
Travere takes rare disease kidney drug to FDA despite failed trial
|
|
Feb 12
|
India’s record breaking streak continued in 2024 – GlobalData
|